Results 161 to 170 of about 40,685 (224)

Identification of a peptide inhibitor disrupting the PCSK9-LDLR interaction <i>via</i> pharmacophore-based virtual screening, molecular dynamics simulations and <i>in vitro/vivo</i> evaluation. [PDF]

J Enzyme Inhib Med Chem
Wu W, Yang S, Liu J, Wang Y, Pan D, Zhou Y.   +5 more
europepmc   +1 more source

Determinants of circulating PCSK9 levels and the efficacy of PCSK9 inhibitor therapies in chronic kidney disease: a systematic review. [PDF]

Eur J Clin Pharmacol
Ábel T, Benczúr B, Csajbókné ÉC.
europepmc   +1 more source

PCSK9 in Cancer: Biological Mechanisms and Implications for Therapeutic Resistance. [PDF]

Biomolecules
Azmi NU, Syahdi RR, Puteri MU, Yanuar A, Kato M, Saputri FC.   +5 more
europepmc   +1 more source

Metabolic Determinants of PCSK9 Regulation in Women with Polycystic Ovary Syndrome: The Role of Insulin Resistance, Obesity, and Tobacco Smoke Exposure. [PDF]

Int J Mol Sci
Niepsuj J, Piwowar A, Franik G, Bizoń A.   +3 more
europepmc   +1 more source

Serum PCSK9 is not independently associated with dyslipidaemia in type 2 diabetes: a paired cross-sectional study. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Okoro PN, Wahab KW, Olarinoye JK, Abayomi BS.   +3 more
europepmc   +1 more source

Prospects of Using PCSK9 Inhibitors for Acute Coronary Syndrome

А. М. Намитоков, В. К. Зафираки, K. V. Karabakhtsieva   +2 more
openalex   +2 more sources

Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses [PDF]

, 2019
Jennifer G. Robinson, Michel Farnier, John J.P. Kastelein, Eli M. Roth, Marja‐Riitta Taskinen, Helen M. Colhoun, Aurélie Brunet, A. Thomas DiCioccio, Guillaume Lecorps, Robert Pordy, Marie T. Baccara‐Dinet, Christopher P. Cannon   +11 more
openalex   +1 more source

Impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on intracranial atherosclerotic plaque characteristics and low density lipoprotein-cholesterol (LDL-C) reduction: a real-world observational study. [PDF]

PeerJ
Li Z, Li X, Zhang Y, Qi J, Ji L, Li S, Gu M, Liu Y, Zhang Y, Mei Y, Wang M, Zhou J, Su M, Zhu L, Deng Q.   +14 more
europepmc   +1 more source

PCSK9 and Atherosclerosis - Lipids and Beyond

, 2017
Michael D. Shapiro, Sergio Fazio
openalex   +2 more sources

PCSK9 inhibitors: a promising lipid-lowering strategy for kidney transplant recipients. [PDF]

Ren Fail
Luo B, Guo L, Di W.
europepmc   +1 more source